Literature DB >> 3933817

Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.

R C Bocian, S Dray, S Ben-Efraim, M B Mokyr.   

Abstract

Exposure of MOPC-315 cells from the primary tumor nodule to a low concentration (0.5 nmol/ml) of melphalan (L-phenylalanine mustard; L-PAM) rendered the tumor cells capable of bringing about the generation of a potent primary antitumor cytotoxic response. Accordingly, the level of antitumor cytotoxicity generated by normal spleen cells immunized in vitro with L-PAm-treated tumor cells was at least five-fold greater than the level generated in response to untreated tumor cells. The marked superiority of L-PAM-treated tumor cells over untreated tumor cells in bringing about the generation of antitumor cytotoxicity was evident over a wide range of responder to stimulator cell ratios. The higher level of antitumor cytotoxicity exhibited by normal spleen cells immunized with L-PAM-treated tumor cells as compared with untreated tumor cells was not merely the result of direct drug-mediated tumoricidal activity, thereby reducing the number of tumor cells present which can act as cold target cell inhibitors during the 51Cr release assay. This is apparent from the observation that the level of antitumor cytotoxicity generated in response to a given percentage of stimulator tumor cells pretreated with 0.5 nmol L-PAM/ml, a drug concentration associated with retention of 60% tumor cell proliferative capacity, is substantially greater than that generated in response to less than half that percentage of untreated stimulator tumor cells. Moreover, stimulator tumor cells exposed to a fully antiproliferative concentration of L-PAM brought about the generation of a higher level of antitumor cytotoxicity than stimulator tumor cells exposed to mitomycin C at a concentration which inhibited the proliferation of the tumor cells to the same extent as the L-PAM. A low concentration of L-PAM which was effective in rendering isolated tumor cells from the primary tumor nodule capable of bringing about the generation of antitumor cytotoxicity was also effective in inducing the appearance of potent antitumor immune potential in tumor bearer splenic cells containing metastatic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933817     DOI: 10.1007/bf00199775

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  38 in total

1.  Differential tumor immunogenicity of L1210 and its sublines. I. Effect of an increased antigen density on tumor cell surfaces on primary B cell responses in vitro.

Authors:  H Fuji; E Mihich; D Pressman
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

2.  Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

Authors:  M Röllinghoff; B T Rouse; N L Warner
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

3.  Immunotherapy of cancer with L-phenylalanine mustard as a hapten.

Authors:  K Arai; H W Wallace; W S Blakemore
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

4.  Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells.

Authors:  A Rios; R L Simmons
Journal:  Int J Cancer       Date:  1974-01-15       Impact factor: 7.396

5.  Human cell lines that elaborate colon-stimulating activity for the marrow cells of man and other species.

Authors:  J F Di Persio; J K Brennan; M A Lichtman; B L Speiser
Journal:  Blood       Date:  1978-03       Impact factor: 22.113

Review 6.  Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules.

Authors:  D Naor
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  In vitro induction of cell-mediated immunity to murine leukemia cells. IV. Amplification of the generation of cytotoxic lymphocytes by enzymatically and chemically modified stimulator leukemic cells.

Authors:  E Kedar; T Lupu
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

9.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Myeloma-induced immunosuppression: a multistep mechanism.

Authors:  J A Katzmann
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

View more
  3 in total

1.  Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.

Authors:  S Shoval; R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.

Authors:  L M Weiskirch; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 3.  Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.

Authors:  S Dray; M B Mokyr
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.